“The Therapy of Elimination First” for Early Acute Mastitis: A Systematic Review and Meta-Analysis

Table 1

Included RCTs.

Study	Location	baseline	Age (years); E/C	Duration (days); E/C	Duration of treatment; (days)	Sample size; E/C	Staging of the; acute mastitis	ADs of experimental; group	FUP; (months)
Liu and Ge, 2009	China	Comparable	27.2/24.5	3.5/3.3	NR	90/90	Galactostasis stage	NR	NR
Chen and Xiao, 2011	China	Comparable	29/29.5	3/2.5	7	30/30	Galactostasis stage	NR	NR
Zhang, 2006	China	NR	NR	NR	7	80/40	Galactostasis stage	NR	NR
Wang and Yin, 2004	China	NR	NR	NR	7	60/30	Galactostasis stage	NR	NR
Wang and Liu, 2014	China	Comparable	28.5/29.5	5.5/5.5	NR	30/30	Galactostasis stage	NR	NR
Yang, 2009	China	Comparable	28/29	NR	7	60/60	Galactostasis stage	NR	NR
Liang and Lou, 2015	China	Comparable	26.68/26.98	13.98/14.28	14	40/30/30	Galactostasis stage	NR	NR
Liu, 2009	China	Comparable	27.6/27.2	4.6/4.5	3	31/31	Galactostasis stage	NR	NR
Tang, 2009	China	Comparable	25.23/26.56	4.5/3.98	7	50/50	Galactostasis stage	NR	1–3
Hu, 2012	China	Comparable	27.45/27.45	4.02/4.02	7	60/60	Galactostasis stage	NR	NR
Fan, 2010	China	NR	28/28	8.5/8.5	4	40/20	Galactostasis stage	NR	NR
Lin and Wang, 2007	China	Comparable	28.5/28	NR	3	25/25	Galactostasis stage	NR	NR
Hou and Lv, 2015	China	Comparable	33.9/35.7	24.6/25.9	NR	600/600	Galactostasis stage	NR	NR
Mao, 1998	China	Comparable	25/25	NR	NR	56/20	Galactostasis stage	NR	NR
Cai and Shen, 2016	China	Comparable	30.30/29.97	2.03/1.93	6	30/30	Galactostasis stage	One patient: diarrhea	NR
Qu et al., 2016	China	Comparable	28/28	3.5	7	40/40	Galactostasis stage	NR	NR

RCTs: randomized controlled trials; E: experimental group; C: control group; ADs: adverse events; FUP: followup period; NR: no report.